Kintara Therapeutics Inc (NASDAQ:KTRA)’s traded shares stood at 1.05 million during the last session, with the company’s beta value hitting 0.80. At the close of trading, the stock’s price was $0.19, to imply an increase of 4.71% or $0.01 in intraday trading. The KTRA share’s 52-week high remains $4.59, putting it -2315.79% down since that peak but still an impressive 57.89% since price per share fell to its 52-week low of $0.08. The company has a valuation of $10.59M, with an average of 8.48 million shares in intraday trading volume over the past 10 days and average of 3.34 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Kintara Therapeutics Inc (KTRA), translating to a mean rating of 2.00. Of 6 analyst(s) looking at the stock, 0 analyst(s) give KTRA a Sell rating. 0 of those analysts rate the stock as Overweight while 2 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Kintara Therapeutics Inc (NASDAQ:KTRA) trade information
After registering a 4.71% upside in the last session, Kintara Therapeutics Inc (KTRA) has traded red over the past five days. The 5-day price performance for the stock is 14.15%, and 6.40% over 30 days. With these gigs, the year-to-date price performance is 12.74%. Short interest in Kintara Therapeutics Inc (NASDAQ:KTRA) saw shorts transact 1.29 million shares and set a 0.92 days time to cover.
KTRA Dividends
Kintara Therapeutics Inc has its next earnings report out in November. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Kintara Therapeutics Inc (NASDAQ:KTRA)’s Major holders
Kintara Therapeutics Inc insiders hold 0.12% of total outstanding shares, with institutional holders owning 1.48% of the shares at 1.48% float percentage. In total, 1.48% institutions holds shares in the company.
